Expression of Cancer Stem Cell Marker CD133 in Malignant Melanoma and Spitz Nevus in a Pediatric Population
R Al Dhaybi, H Sartelet, J Powell, V Kokta. CHU Sainte Justine, University of Montreal, Montreal, QC, Canada
Background: Identification of cancer stem cell markers, such as CD133, may help refine classification, diagnosis and treatment of cancers including malignant melanoma. The role of CD133 protein as a factor serving in directing tumor growth is the subject of debate.
Design: We evaluated the immunohistochemical expression of CD133 in 12 malignant melanomas and in 20 Spitz nevi, diagnosed between 1990 and 2008, in our pediatric population. We reviewed the charts of these patients and noted their clinical evolution.
Results: CD133 was positive in 4 cases of our childhood malignant melanoma series. The latter were the only malignant melanoma cases that were associated with either lymph node or visceral metastases and/or death. CD133 was negative in all 20 cases of Spitz nevi.
Figure 1: Positive CD133 (red) in multifocal melanoma cells, revealing clear cytoplasmic staining with focal membranous re-enforcement (green arrows), x 400 magnification.
Conclusions: CD133 positive cancer stem cell expression might correlate with bad prognosis (metastasis and/or death) in childhood malignant melanoma. Treatment targeting these cancer stem cells could decrease the chemoresistance of malignant melanoma in the pediatric population.
Wednesday, March 24, 2010 1:00 PM
Poster Session VI # 74, Wednesday Afternoon